Methods and compositions for targeting pd-l1
AssigneeAligos Therapeutics, Inc.
InventorsLeonid Beigelman, Megan Elizabeth Fitzgerald, Saul Martinez Montero, Aneerban Bhattacharya
Life of this patent
Estimating the term…
Loading patent…
AssigneeAligos Therapeutics, Inc.
InventorsLeonid Beigelman, Megan Elizabeth Fitzgerald, Saul Martinez Montero, Aneerban Bhattacharya
Estimating the term…
The present disclosure relates to small interfering RNA (siRNA) molecules directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The siRNA can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of siRNAs and uses of or methods of using the siRNAs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
A small interfering RNA (siRNA) that targets human CD274 mRNA, comprising a sense strand and an antisense strand, wherein the antisense strand comprises 18 to 21 nucleotides selected from the group consisting of unmodified nucleotides and modified nucleosides,
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.